Simparica TRIO Chews for Dogs 44.1-88 lbs (20.1-40 kg)

Description

Simparica TRIO Chews for Dogs 44.1–88 lbs (20.1–40 kg) is a monthly oral chewable from Zoetis that combines 48 mg sarolaner, 0.72 mg moxidectin, and 200 mg pyrantel in a single tablet. Designed for dogs weighing 44.1–88 lbs (20.1–40 kg), it is suitable for many large breeds, including retrievers, shepherds, setters, and other similarly sized working dogs. Each monthly dose provides protection against fleas, six species of ticks, developing heartworm larvae, and intestinal parasites such as roundworms and hookworms.

Recommended for

Dogs weighing 44.1 to 88 lbs (20.1 to 40 kg) from 8 weeks of age and older.

Indication/Coverage

For dogs suffering from, or at risk of, mixed parasitic infections, Simparica TRIO provides the following coverage:

• Heartworm prevention: Prevention of heartworm disease caused by Dirofilaria immitis through elimination of susceptible L3/L4 larval stages.
• Flea treatment and prevention: Elimination of adult fleas (Ctenocephalides felis); prevents re-establishment of flea infestations within each monthly dosing cycle.
• Tapeworm prevention: Prevents Dipylidium caninum infections as a direct consequence of eliminating Ctenocephalides felis vector fleas on the treated dog.
• Tick treatment and control: Treatment and control of infestations with Amblyomma americanum (lone star tick), Amblyomma maculatum (Gulf Coast tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), Rhipicephalus sanguineus (brown dog tick), and Haemaphysalis longicornis (Asian longhorned tick).
• Lyme disease prevention: Prevents Borrelia burgdorferi infection as a direct result of eliminating Ixodes scapularis vector ticks on the treated dog.
• Roundworm treatment and control: Treatment and control of Toxocara canis (immature adults and adults) and Toxascaris leonina (adults).
• Hookworm treatment and control: Treatment and control of Ancylostoma caninum (L4 larvae, immature adults, and adults) and Uncinaria stenocephala (adults).

Key Benefits

The points below reflect what the Zoetis product label and clinical study data established for dogs in the 44.1 to 88 lb weight band:

• Single-tablet broad coverage: One monthly chewable delivers sarolaner against fleas and six tick species, moxidectin against heartworm larvae, and pyrantel against intestinal nematodes, removing the need to coordinate administration of three separate parasite products.
• Validated from 8 weeks: Dogs as young as 8 weeks and weighing at least 44.1 lbs (20.1 kg) are within the labeled population, providing a defined starting point for prevention in large-breed puppies that reach this weight band early.
• Rapid flea kill from first dose: Laboratory data confirm that Simparica TRIO begins eliminating adult fleas at 4 hours post-administration and reaches 100% efficacy at 8 hours, interrupting flea feeding and egg deposition on the day of dosing.
• Sustained multi-tick efficacy: Against scapularis, efficacy of at least 94.2% within 24 hours of infestation is maintained across the full 28-day interval; against A. americanum, at least 99.4% efficacy is reached within 72 hours, covering the range of tick species most likely to infest large dogs with outdoor access.
• Intestinal nematode clearance in one dose: Pyrantel pamoate functions as a depolarizing neuromuscular blocker targeting caninum at L4, immature adult, and adult stages, resolving established hookworm and roundworm infections without a separate deworming product.
• Systemic action unaffected by bathing: Sarolaner and moxidectin distribute systemically via plasma after oral absorption; water exposure, bathing, or rain does not diminish efficacy, which is a practical consideration for large working and sporting breeds with frequent outdoor and water activity.
• Lyme disease prevention for field dogs: Two controlled laboratory studies confirmed that Simparica TRIO prevented Borrelia burgdorferi transmission following scapularis infestation at 28 days post-treatment, directly relevant to large-breed dogs used for hunting, herding, or trail work in tick-endemic regions.
• Palatability for large-breed dogs: The flavored chewable format is accepted as a treat by most dogs in this weight range, avoiding the handling challenges associated with spot-on application to thick, double-layered, or dense coats common in large breeds.

Caution

Hazards to Humans

Keep out of reach of children. Simparica TRIO is formulated for oral administration to dogs; human ingestion requires immediate medical attention. Wash hands thoroughly after handling tablets and before any food preparation or contact. Avoid transferring tablet residue to eyes or broken skin.

Hazards to Domestic Animals

Simparica TRIO is for oral use in dogs only; do not administer to cats or other species. This variant is not appropriate for dogs below 44.1 lbs (20.1 kg) or younger than 8 weeks of age. Sarolaner is an isoxazoline-class compound linked to neurologic adverse reactions including tremors, ataxia, and seizures; use with caution in dogs with a history of seizures or neurological disorders. Zoetis has not evaluated the safety of Simparica TRIO in breeding, pregnant, or lactating dogs; a veterinarian should be consulted before use in these animals. Debilitated dogs or those on concurrent medications require veterinary assessment prior to administration.

Possible Side Effects

Monitor your dog after each Simparica TRIO administration, with close observation during the 24 to 48 hours following the initial dose.

The adverse reactions below were captured across three field safety studies conducted by Zoetis; primary incidence data are drawn from 272 dogs dosed monthly for up to 11 treatment cycles:

• Vomiting: Reported in 14.3% of treated dogs in the primary field study; the highest-frequency adverse reaction across all three studies, also observed in dogs enrolled in the flea and roundworm treatment studies.
• Diarrhea: Recorded in 13.2% of treated dogs, with or without blood in post-approval reports; incidence was higher in dogs that harboured active roundworm infections at the time of first administration.
• Lethargy: Observed in 8.5% of treated dogs; generally self-limiting and transient across the study population.
• Anorexia: Reported in 5.1% of treated dogs, at a rate comparable to the active control group in the primary study.
• Polyuria: Observed in 3.7% of treated dogs within the primary field study.
• Hyperactivity: Reported in 2.2% of the Simparica TRIO group versus 0.7% in the active control group.
• Seizures: Confirmed in one dog in a controlled laboratory study 16 days post-administration; post-approval FDA/CVM data classify seizure as a known risk across the isoxazoline drug class.
• Muscle tremors and ataxia: Present in post-approval adverse drug experience reports filed with FDA/CVM; frequency cannot be reliably quantified from spontaneous post-market submissions alone.

Discontinue use and contact a veterinarian if any reaction persists or intensifies after dosing.